Overview

Survivorship in the Era of Immuno-Oncology

As more patients are treated with immunotherapies for cancer, increasing numbers of patients with metastatic disease are transitioning in survivorship. Patients who respond to immuno-oncology therapy may be exposed to treatment for months or even years. Thus, the survivorship experience for many patients with metastatic disease has changed significantly due to this new treatment paradigm. This ACCC education project provides “frame-the-issue” panel discussions with multidisciplinary experts who provide perspective on the unique emotional, physical, and financial survivorship needs of the growing IO patient population.